




World Health  
Organization

Guideline:

**Intermittent iron  
supplementation in  
preschool and  
school-age children**



WHO Library Cataloguing-in-Publication Data

Guideline: Intermittent iron supplementation in preschool and school-age children.

1.Iron – administration and dosage. 2.Anaemia, Iron-deficiency – prevention and control. 3.Child, Preschool. 4.Child. 5.Dietary supplements. 6.Guidelines. I.World Health Organization.

ISBN 978 92 4 150200 9

(NLM classification: WH 160)

© **World Health Organization 2011**

All rights reserved. Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site ([http://www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.


All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Design and layout: Alberto March

## Suggested citation

WHO. *Guideline: Intermittent iron supplementation in preschool and school-age children*. Geneva, World Health Organization, 2011.

<b>Contents</b>	Acknowledgements	iv
	Financial support	iv
	Summary	1
	Scope and purpose	2
	Background	2
	Summary of evidence	3
	Recommendation	5
	Remarks	6
	Dissemination, adaptation and implementation	7
	<i>Dissemination</i>	
	<i>Adaptation and implementation</i>	
	<i>Monitoring and evaluation of guideline implementation</i>	
	Implications for future research	8
	Guideline development process	9
	<i>Advisory groups</i>	
	<i>Scope of the guideline, evidence appraisal and decision-making</i>	
	Management of conflicts of interest	11
	Plans for updating the guideline	12
	References	13
<b>Annex 1</b>	GRADE “Summary of findings” tables	15
<b>Annex 2</b>	WHO Steering Committee for Nutrition Guidelines Development	17
<b>Annex 3</b>	Nutrition Guidance Expert Advisory Group (NUGAG) – Micronutrients, WHO Secretariat and external resource experts	18
<b>Annex 4</b>	External Experts and Stakeholders Panel – Micronutrients	22
<b>Annex 5</b>	Questions in Population, Intervention, Control, Outcomes (PICO) format	25
<b>Annex 6</b>	Summary of NUGAG members’ considerations for determining the strength of the recommendation	27



## Acknowledgements

This guideline was coordinated by Dr Luz Maria De-Regil under the supervision of Dr Juan Pablo Peña-Rosas, with technical input from Dr Metin Gulmezoglu, Dr Jose Martines, Dr Matthews Mathai and Dr Lisa Rogers. Thanks are due to Dr Regina Kulier and the staff at the Guidelines Review Committee Secretariat for their support throughout the process. Thanks to also due to Dr Davina Gheri for her technical advice and assistance in the preparation of the technical consultations for this guideline and Mr Issa T. Matta and Mrs Chantal Streijffert Garon from the World Health Organization (WHO) Office of the Legal Counsel for their support in the management of conflicts of interest procedures. Ms Grace Rob and Mrs Paule Pillard from the Micronutrients Unit, Department of Nutrition for Health and Development, provided logistic support.

WHO gratefully acknowledges the technical input of the WHO Nutrition Steering Committee and the Nutrition Guidance Expert Advisory Group (NUGAG), especially the chairs of the meetings, Dr Janet King, Dr Rebecca Stoltzfus and Dr Rafael Flores-Ayala. WHO is also grateful to the Cochrane Developmental, Psychosocial and Learning Problems Group staff for their support during the development of the systematic review used to inform this guideline.

## Financial support

WHO thanks the Government of Luxembourg for providing financial support for this work.

**Summary**

It is estimated that 600 million preschool and school-age children worldwide are anaemic, and it is assumed that at least half of these cases are attributable to iron deficiency. Member States have requested guidance from the World Health Organization (WHO) on the effects and safety of intermittent iron supplementation in children as a public health intervention to improve their iron status and reduce the risk of developing iron deficiency anaemia, in support of country efforts to achieve the Millennium Development Goals.

WHO has developed the present evidence-informed recommendations using the procedures outlined in the [WHO handbook for guideline development](#). The steps in this process included: (i) identification of priority questions and outcomes; (ii) retrieval of the evidence; (iii) assessment and synthesis of the evidence; (iv) formulation of recommendations, including research priorities; and (v) planning for dissemination, implementation, impact evaluation and updating of the guideline. The Grading of Recommendations Assessment, Development and Evaluation ([GRADE](#)) methodology was used to prepare evidence profiles related to preselected topics, based on up-to-date systematic reviews.

The guideline development group for nutrition interventions, the Nutrition Guidance Expert Advisory Group (NUGAG), comprises content experts, methodologists, representatives of potential stakeholders and consumers. These experts participated in several WHO technical consultations concerning this guideline, held in Geneva, Switzerland, and Amman, Jordan, in 2010 and 2011. Members of the External Experts and Stakeholders Panel were identified through a public call for comments, and this panel was involved throughout the guideline development process. NUGAG members voted on the strength of the recommendation, taking into consideration: (i) desirable and undesirable effects of this intervention; (ii) the quality of the available evidence; (iii) values and preferences related to the intervention in different settings; and (iv) the cost of options available to health-care workers in different settings. All NUGAG members completed a Declaration of Interests Form before each meeting.

In settings where the prevalence of anaemia in preschool or school-age children is 20% or higher, intermittent use of iron supplements is recommended as a public health intervention to improve iron status and reduce the risk of anaemia among children (strong recommendation). In comparison with a placebo or no intervention, the overall quality of the available evidence was found to be moderate for anaemia, low for haemoglobin and ferritin concentrations and very low for iron deficiency. When compared with daily supplementation, the quality of the available evidence for intermittent supplementation with regard to anaemia and haemoglobin and ferritin concentrations was found to be low and for iron deficiency it was very low.

<sup>1</sup> A WHO guideline is any document, whatever its title, containing WHO recommendations about health interventions, whether they be clinical, public health or policy interventions. A recommendation provides information about what policy-makers, health-care providers or patients should do. It implies a choice between different interventions that have an impact on health and that have ramifications for the use of resources. All publications containing WHO recommendations are approved by the WHO Guidelines Review Committee.

---

## Scope and purpose

This guideline provides global, evidence-informed recommendations on the intermittent use of iron supplements for preschool and school-age children as a public health intervention to improve iron status and reduce the risk of childhood iron deficiency anaemia.

The guideline will help Member States and their partners in their efforts to make informed decisions on the appropriate nutrition actions to achieve the Millennium Development Goals, in particular, the eradication of extreme poverty and hunger (MDG 1), achievement of universal primary education (MDG 2) and reduction of child mortality (MDG 4). The guideline is intended for a wide audience including policy makers, their expert advisers, and technical and programme staff at organizations involved in the design, implementation and scaling-up of nutrition actions for public health.

This document presents the key recommendation and a summary of the supporting evidence. Further details of the evidence base are provided in Annex 1 and other documents listed in the references.

## Background

Iron deficiency, a common form of nutritional deficiency during childhood, results from sustained negative iron balance, which is caused by inadequate dietary intake, absorption or utilization of iron, increased iron requirements during the growth period, or blood loss due to parasitic infections such as malaria, soil-transmitted helminth infestations and schistosomiasis. In later stages of iron depletion, the haemoglobin concentration decreases, resulting in anaemia. Anaemia is characterized by a reduction in the oxygen-carrying capacity of blood, such that the physiological oxygen needs of the affected individual can no longer be met. In addition to iron deficiency, other micronutrient deficiencies (e.g. folate, vitamin B<sub>12</sub> and vitamin A), chronic inflammation and inherited disorders of haemoglobin structure can all cause anaemia (1). Diagnosis of anaemia requires measurement of the haemoglobin concentration, while serum ferritin and serum soluble transferrin receptor levels are commonly used as indicators of iron status. A diagnosis of iron deficiency anaemia is made when there is both anaemia and iron deficiency (2).

Children are particularly vulnerable to iron deficiency anaemia because of their increased iron requirements in the periods of rapid growth, especially in the first 5 years of life. It is estimated that worldwide, 600 million preschool and school-age children are anaemic, and it is assumed that at least half of these cases are attributable to iron deficiency (3). Iron deficiency anaemia in children has been linked to increased childhood morbidity and impaired cognitive development and school performance. Both epidemiological and experimental data suggest that when these impairments occur at an early age, they may be irreversible, even after repletion of iron stores, thus reinforcing the importance of preventing this condition (4, 5).

---

Public health interventions to ameliorate micronutrient malnutrition in preschool and school-age children include the promotion of dietary diversification to include foods rich in highly absorbable vitamins and minerals, anthelmintic treatment, mass fortification of staple foods and condiments, home (point of use) fortification of foods, and provision of micronutrient supplements (6). The effectiveness of such interventions in these age groups is variable and not always aimed at meeting children's needs (for example, in the case of mass fortification) whereas in other cases the interventions are not feasible because of economic or behavioural constraints (7). Although daily iron supplementation has proven to be effective in increasing haemoglobin concentrations in children, especially in those who are anaemic (8), in real-world settings, the low coverage rates and insufficient tablet distribution, the prolonged duration of the intervention and the associated side-effects (e.g. gastrointestinal discomfort, constipation and staining of teeth with drops or syrups) may limit adherence to the intervention, especially in young children (7, 9).

Intermittent use of oral iron supplements (i.e. once, twice or three times a week on non-consecutive days) has been proposed as an effective alternative to daily iron supplementation to prevent anaemia among children (10, 11). The proposed rationale behind this intervention is that intestinal cells turn over every 5–6 days and have limited iron absorptive capacity. Thus intermittent provision of iron would expose only the new epithelial cells to this nutrient, which should, in theory, improve the efficiency of absorption (12, 13). Intermittent supplementation also may minimize blockage of absorption of other minerals due to the high iron levels in the gut lumen and in the intestinal epithelium (14). This overall reduced exposure to iron is particularly relevant in malaria settings (where it has been suggested that the provision of additional iron may exacerbate the infection) as less iron may be available for the parasite's growth (15). Experience in different populations has shown that intermittent regimens reduce the frequency of other side-effects associated with daily iron supplementation and are also more acceptable to recipients, thus increasing compliance with supplementation programmes (16).

### Summary of evidence

A Cochrane systematic review (17) was conducted to assess the effects and safety of intermittent iron supplementation alone or in combination with other micronutrients in children under 12 years of age with regard to health and nutrition outcomes. The review compared the provision of iron supplements on an intermittent basis versus no intervention or placebo, and versus daily use of iron supplements, among children living in a variety of settings, including malaria-endemic areas.

The outcomes considered to be critical for decision-making by the Nutrition Guidance Expert Advisory Group (NUGAG) were anaemia, haemoglobin concentration, iron status and mortality. The potential modifying effects of the baseline anaemia prevalence, total iron dose per week, the intermittent regimen scheme, duration of the intervention, supplement formulation and sex were also assessed.

---

The review included 33 randomized controlled trials involving 13 144 children from 20 countries in Latin America, Africa and Asia where anaemia prevalence was moderate to high. Most of the trials used ferrous sulfate as the iron source, with doses ranging from 7.5 mg to 200 mg of elemental iron per week. In five studies, iron was given in combination with folic acid, in doses that ranged from 100 µg (0.1 mg) to 500 µg (0.5 mg) per week.

Compared with placebo or no intervention, intermittent iron supplementation (alone or in combination with other nutrients) in children younger than 12 years of age significantly increased the concentration of haemoglobin (mean difference (MD) 5.20 g/l, 95% confidence interval (CI) 2.51–7.88, 19 studies) and ferritin (MD 14.17 µg/l, 95% CI 3.53–24.81, five studies), and reduced the risk of presenting anaemia at the end of the intervention (relative risk (RR) 0.51, 95% CI 0.37–0.72, 10 studies).

On the other hand, compared with children receiving daily iron supplements, those receiving iron supplements intermittently were more likely to be anaemic at the end of the intervention (RR 1.23, 95% CI 1.04–1.47, six studies) but the mean difference in the haemoglobin and ferritin concentrations between the two groups was not significant (MD –0.60, g/l 95% CI –1.54 to 0.35, 19 studies, and –4.19 µg/l, 95% CI –9.42 to 1.05, 10 studies, respectively). Adherence tended to be higher among children receiving intermittent supplementation compared with those receiving daily supplementation, although this result was not statistically significant.

The micronutrient composition of the supplements (iron alone, iron plus folic acid, or iron plus other micronutrients) did not impact on the above findings, although most of the evidence was derived from trials using supplements containing only iron. In addition, the intervention seemed efficacious in settings with different baseline prevalence of anaemia, in both sexes, across trials lasting either less or more than 3 months and with all intermittent regimens.

No deaths were reported in the trials. Although limited data were available on outcomes related to morbidity, neurocognitive outcomes, other indicators of vitamin and mineral status, and side-effects, no evidence was found of increased morbidity or side-effects, including in malaria-endemic settings.

In comparison with a placebo or no intervention, the overall quality of the available evidence was found to be moderate for anaemia, low for haemoglobin and ferritin concentrations and very low for iron deficiency. When compared with daily supplementation, the quality of the available evidence for intermittent supplementation with regard to anaemia and haemoglobin and ferritin concentrations was found to be low and for iron deficiency it was very low (Annex 1).

## Recommendation

Intermittent iron supplementation is recommended as a public health intervention in preschool and school-age children to improve iron status and reduce the risk of anaemia (*strong recommendation*)<sup>1</sup>.

The suggested schemes for intermittent iron supplementation in preschool and school-age children are presented in Table 1.

Table 1

### Suggested schemes for intermittent iron supplementation in preschool and school-age children

Target group	Preschool-age children (24–59 months)	School-age children (5–12 years)
Supplement composition	25 mg of elemental iron <sup>a</sup>	45 mg of elemental iron <sup>b</sup>
Supplement form	Drops/syrups	Tablets/capsules
Frequency	One supplement per week	
Duration and time interval between periods of supplementation	3 months of supplementation followed by 3 months of no supplementation after which the provision of supplements should restart If feasible, intermittent supplements could be given throughout the school or calendar year	
Settings	Where the prevalence of anaemia in preschool or school-age children is 20% or higher	

<sup>a</sup> 25 mg of elemental iron equals 75 mg of ferrous fumarate, 125 mg of ferrous sulfate heptahydrate or 210 mg of ferrous gluconate.

<sup>b</sup> 45 mg of elemental iron equals 135 mg of ferrous fumarate, 225 mg of ferrous sulfate heptahydrate or 375 mg of ferrous gluconate.

<sup>1</sup> A strong recommendation is one for which the guideline development group is confident that the desirable effects of adherence outweigh the undesirable effects. This can be either in favour of or against an intervention. Implications of a strong recommendation for patients are that most people in their situation would desire the recommended course of action and only a small proportion would not. Implications for clinicians are that most patients should receive the recommended course of action, and adherence to this recommendation is a reasonable measure of good-quality care. With regard to policy-makers, a strong recommendation means that it can be adapted as a policy in most situations.

## Remarks

- In malaria-endemic areas, the provision of iron supplements should be implemented in conjunction with adequate measures to prevent, diagnose and treat malaria (18, 19).
- Intermittent iron supplementation is a preventive strategy for implementation at population level. If a child is diagnosed with anaemia in a clinical setting, he or she should be treated with daily iron supplementation until the haemoglobin concentration rises to normal (20). He or she can then be switched to an intermittent regimen to prevent the recurrence of anaemia.
- As there is limited evidence for the effective dose of folic acid or other vitamins and minerals for intermittent supplementation, it is suggested providing two times the recommended nutrient intake in these age groups without exceeding the daily upper limit (21). Thus children 24–59 months of age may be given a dose of 300 µg (0.3 mg) of folic acid once a week, whereas older children may be given 400 µg (0.4 mg).
- Where infection with hookworm is endemic (prevalence 20% or greater) it may be more effective to combine iron supplementation with anthelmintic treatment in children above the age of 5 years. Universal anthelmintic treatment, irrespective of infection status, is recommended at least annually in these areas (20, 22).
- The provision of iron supplements on an intermittent basis may be integrated into school or community programmes to reach the target populations. These programmes should ensure that the daily nutritional needs of preschool or school-age children are met and not exceeded, through the evaluation of nutritional status and intake, as well as consideration of existing anaemia and micronutrient deficiency control measures (such as provision of vitamin A supplements, fortified foods and anthelmintic therapy).
- The intermittent provision of supplements may include a behaviour communication change strategy that promotes the awareness and correct use of this product along with other practices such as hand washing with soap, prompt attention to fever in malaria settings, and measures to manage diarrhoea, particularly among younger children (23).
- The establishment of a quality assurance process is important to ensure that supplements are manufactured, packaged and stored in a controlled and uncontaminated environment (24).
- The selection of the most appropriate delivery platform should be context-specific, with the aim of ensuring that the most vulnerable members of the populations are reached. For example, if the education system is selected as delivery channel, efforts should be made to reach children who do not attend school.
- Oral supplements are available as drops or syrups for preschool-age children, and tablets or capsules for school-age children. Liquid preparations for oral use are usually supplied as solutions, emulsions or suspensions containing one or more of the active ingredients in a suitable vehicle. All these preparations are supplied either in the finished form or, with the exception of oral emulsions,

---

may need to be prepared just before use by dissolving or dispersing the granules or powder in the vehicle as stated on the label. Tablets (soluble tablets, effervescent tablets, dissolvable tablets for use in the mouth and modified-release tablets) are solid dosage forms containing one or more active ingredients. They are manufactured by single or multiple compression (in certain cases they are moulded) and may be uncoated or coated. Capsules are solid dosage forms with hard or soft shells, which are available in a variety of shapes and sizes, and contain a single dose of one or more of the active ingredients (25).

## Dissemination, adaptation and implementation

### *Dissemination*

The current guideline will be disseminated through electronic media such as slide presentations, CD-ROMs and the World Wide Web, either through the WHO Micronutrients and United Nations Standing Committee on Nutrition (SCN) mailing lists or the [WHO nutrition web site](#). The Department of Nutrition for Health and Development has developed the WHO electronic Library of Evidence for Nutrition Actions (eLENA). This library aims to compile and display WHO guidelines related to nutrition, along with complementary documents such as systematic reviews and other evidence that informed the guidelines, biological and behavioural rationales, and additional resources produced by Member States and global partners. In addition, the guideline will be disseminated through a broad network of international partners, including WHO country and regional offices, ministries of health, WHO collaborating centres, universities, other United Nations agencies and nongovernmental organizations.

### *Adaptation and implementation*

As this is a global guideline it should be adapted to the context of each Member State. Prior to implementation, an iron supplementation programme should have well-defined objectives that take into account available resources, existing policies, suitable delivery platforms and suppliers, communication channels and potential stakeholders. Supplementation programmes should start with a pilot and scaled up as experience and evidence grow and resources allow. Ideally, an iron supplementation programme should be implemented as part of an integrated strategy to control nutritional deficiencies.

To ensure that WHO global guidelines and other evidence-informed recommendations for micronutrient interventions are better implemented in low- and middle-income countries, the Department of Nutrition for Health and Development works with the WHO Evidence-Informed Policy Network (EVIPNet) programme. EVIPNet promotes partnerships at country level between policy-makers, researchers and civil society to facilitate policy development and implementation through use of the best available evidence.

---

### *Monitoring and evaluation of guideline implementation*

A plan for monitoring and evaluation with appropriate indicators is encouraged at all stages. The impact of this guideline can be evaluated within countries (i.e. monitoring and evaluation of the programmes implemented at scale) and across countries (i.e. the adoption and adaptation of the guideline globally). The WHO Department of Nutrition for Health and Development, Micronutrients Unit, jointly with the Centers for Disease Control and Prevention (CDC) International Micronutrient Malnutrition Prevention and Control (IMMPaCt) programme, and with input from international partners, has developed a generic logic model for micronutrient interventions in public health to depict the plausible relationships between inputs and expected MDGs by applying the micronutrient programme evaluation theory. Member States can adjust this model and use it in combination with appropriate indicators, for designing, implementing, monitoring and evaluating the successful scaling-up of nutrition actions (26).

For evaluation at global level, the WHO Department of Nutrition for Health and Development is developing a centralized platform for sharing information on nutrition actions in public health practice implemented around the world. By sharing programmatic details, specific country adaptations, and lessons learnt, this platform will provide examples of how guidelines are being translated into nutrition actions.

### **Implications for future research**

Discussion with NUGAG members and stakeholders highlighted the limited evidence in some areas, meriting further research on intermittent iron supplementation in preschool and school-age children, in particular, in the following areas:

- the most effective and safe dose of folic acid that can be provided intermittently;
- provision of multiple micronutrients on an intermittent basis and their effects on other indicators of vitamin and mineral status, such as retinol and zinc;
- efficacy of intermittent iron regimens with regard to neurocognitive and developmental outcomes and growth (attempts should be made to use comparable measures across studies when possible);
- efficacy of intermittent supplementation in the treatment of anaemia, iron deficiency and iron deficiency anaemia, as well as the best therapeutic regimen (dose, frequency, duration);
- cost-effectiveness of intermittent compared with daily iron supplementation, taking into account more than just the cost differential of the supplements themselves;
- whether this intervention requires continuous or periodic implementation over the year, taking into account both biological and programmatic feasibility.

---

In addition, future studies are encouraged to comprehensively document the effects of intermittent supplementation on anaemia, iron deficiency, haemoglobin and ferritin concentrations and other indicators of iron status and inflammation. Reporting of side-effects in greater detail according to recommended definitions is highly desirable to better understand the factors influencing adherence. A more systematic and comparable reporting system addressing the relevance of direct and continued supervision is also needed.

## Guideline development process

This guideline was developed in accordance with WHO evidence-informed guideline development procedures, as outlined in the [WHO handbook for guideline development](#) (27).

### *Advisory groups*

A WHO Steering Committee for Nutrition Guidelines Development, led by the Department of Nutrition for Health and Development and the Department of Research Policy and Cooperation, was established in 2009 with representatives from all WHO departments with an interest in the provision of scientific nutrition advice including Child and Adolescent Health and Development, Reproductive Health and Research, and the Global Malaria Programme. The Steering Committee guided the development of this guideline and provided overall supervision of the guideline development process (Annex 2). Two additional groups were formed: an advisory guideline group and an External Experts and Stakeholders Panel.

The Nutrition Guidance Expert Advisory Group, NUGAG, was also established in 2009 (Annex 3). NUGAG consists of four subgroups: (i) Micronutrients, (ii) Diet and Health, (iii) Nutrition in Life course and Undernutrition, and (iv) Monitoring and Evaluation. Its role is to advise WHO on the choice of important outcomes for decision-making and in the interpretation of the evidence. The group includes experts from various [WHO expert advisory panels](#) and those identified through open calls for specialists, taking into consideration a balanced gender mix, multiple disciplinary areas of expertise and representation from all WHO regions. Efforts were made to include content experts, methodologists, representatives of potential stakeholders (such as managers and other health professionals involved in the health-care process) and consumers. Representatives of commercial organizations may not be members of a WHO guideline group.

The External Experts and Stakeholders Panel was consulted on the scope of the guideline, the questions addressed, and the choice of important outcomes for decision-making, as well as with regard to review of the completed draft guideline (Annex 4). This was done through the WHO Micronutrients and SCN mailing lists that together include over 5500 subscribers, and through the [WHO nutrition web site](#).

### *Scope of the guideline, evidence appraisal and decision-making*

An initial set of questions (and the components of the questions) to be addressed in the guideline was the critical starting point for formulating the recommendation. The questions were drafted by technical staff at the Micronutrients Unit, Department of

---

Nutrition for Health and Development, based on policy and programme guidance needs of Member States and their partners. The population, intervention, control, outcomes (PICO) format was used (Annex 5). The questions were discussed and reviewed by the WHO Steering Committee for Nutrition Guidelines Development, and feedback was received from 48 stakeholders.

The first NUGAG meeting was held on 22–26 February 2010 in Geneva, Switzerland, to finalize the scope of the questions and rank the critical outcomes and populations of interest. The NUGAG – Micronutrients Subgroup discussed the relevance of the questions and modified them as needed. The guideline group members scored the relative importance of each outcome from 1 to 9 (where 7–9 indicated that the outcome was critical for a decision, 4–6 indicated that it was important and 1–3 indicated that it was not important). The final key questions on the use of iron supplements in children 24–59 months of age and those 60 months and older, along with the outcomes that were identified as critical and important for decision-making are listed using the PICO format in Annex 5.

WHO staff, in collaboration with researchers from other institutions, summarized and appraised the evidence by using the Cochrane methodology for randomized controlled trials.<sup>1</sup> For identifying unpublished studies or trials still in progress, a standard procedure was followed to contact more than 10 international organizations working on micronutrients interventions. In addition, the International Clinical Trials Registry Platform (ICTRP), hosted at WHO, was systematically searched for any trials still in progress. No language restrictions were applied to the search. Evidence summaries were prepared according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the overall quality of the evidence (28). GRADE considers the study design; the limitations of the studies in terms of their conduct and analysis; the consistency of the results across the available studies; the directness (or applicability and external validity) of the evidence with respect to the populations, interventions and settings where the proposed intervention may be used; and the precision of the summary estimate of the effect.

Both the systematic reviews and the GRADE evidence profiles for each of the critical outcomes were used for drafting this guideline. The draft recommendation was discussed by the WHO Nutrition Guidance Steering Committee and NUGAG at a second NUGAG consultation, held on 15–18 November 2010, in Amman, Jordan, and the third consultation, held on 14–16 March 2011 in Geneva, Switzerland, where NUGAG members also voted on the strength of the recommendation, taking into account: (i) desirable and undesirable effects of this intervention; (ii) the quality of the available evidence; (iii) values and preferences related to the intervention in different settings; and (iv) the cost of options available to health-care workers in different settings (Annex 6). Consensus was defined as agreement by simple majority of guideline group members. WHO staff present at the meeting as well as other external

---

<sup>1</sup> As part of the Cochrane pre-publication editorial process, this review was commented on by three external peers (an editor, and two referees who are external to the editorial team) and the group's statistical adviser (<http://www.cochrane.org/cochrane-reviews>). The *Cochrane handbook for systematic reviews of interventions* describes in detail the process of preparing and maintaining Cochrane systematic reviews on the effects of health-care interventions.

---

technical experts involved in the collection and grading of the evidence were not allowed to vote. There were no strong disagreements among the guideline group members.

A public call for comments on the final draft guideline was then released. All interested stakeholders became members of the External Experts and Stakeholders Panel but were only allowed to comment on the draft guideline after submitting a signed Declaration of Interests Form. Feedback was received from 15 stakeholders. WHO staff then finalized the guideline and submitted it for clearance by WHO before publication.

### Management of conflicts of interest

According to the rules in the WHO [Basic documents](#) (29), all experts participating in WHO meetings must declare any interest relevant to the meeting prior to their participation. The conflicts of interest statements for all guideline group members were reviewed by the responsible technical officer and the relevant departments before finalization of the group composition and invitation to attend a guideline group meeting. All guideline group members and participants of the guideline development meetings submitted a Declaration of Interests Form along with their curriculum vitae before each meeting. In addition, they verbally declared potential conflicts of interest at the beginning of each meeting. The procedures for management of conflicts of interests strictly followed WHO *Guidelines for declaration of interests (WHO experts)* (30). The potential conflicts of interest declared by members of the guideline group are summarized below.

- Dr Héctor Bourges Rodriguez declared being chair of the executive board of the Danone Institute in Mexico (DIM), a non-profit organization promoting research and dissemination of scientific knowledge in nutrition, and receiving funds as chair honorarium from DIM. Some of the activities of the DIM may generally relate to nutrition and are funded by Danone Mexico, a food producer.
- Dr Norm Campbell at the first meeting declared owning stock in Viterra, a wheat pool for farmers that neither manufactures products nor has activities related to this guideline. In 2011, Dr Campbell declared no longer owning stocks in this company. He serves as a Pan American Health Organization (PAHO) consultant and has been an adviser to Health Canada and Blood Pressure Canada, both of which are government agencies.
- Dr Emorn Wasantwisut declared serving as a technical/scientific adviser to the International Life Sciences Institute (ILSI)/South East Asia's Food and Nutrients in Health and Disease Cluster and as a reviewer of technical documents and speaker for Mead Johnson Nutritionals. Her research unit received funds for research support from Sight and Life and the International Atomic Energy Agency (IAEA) for the use of stable isotopes to define interactions of vitamin A and iron.

- 
- Dr Beverly Biggs declared that the University of Melbourne received funding from the National Health and Medical Research Council (NHMRC) and Australian Research Council (ARC) for research on weekly iron and folic acid supplementation in pregnancy, which was conducted in collaboration with the Research and Training Center for Community Development (RTCCD), the Key Centre for Women’s Health and the Murdoch Childrens Research Institute.

### Plans for updating the guideline

This guideline will be reviewed in 2015. If new information is available at that time, a guideline review group will be convened to evaluate the new evidence and revise the recommendation if needed. The Department of Nutrition for Health and Development at the WHO headquarters in Geneva, along with its internal partners will be responsible for coordinating the guideline update following formal [WHO handbook for guideline development](#) procedures (27). WHO welcomes suggestions regarding additional questions for evaluation in the guideline when it is due for review.

## References

1. WHO/UNICEF/UNU. *Iron deficiency anaemia assessment, prevention and control: a guide for programme managers*. Geneva, World Health Organization, 2001 ([http://whqlibdoc.who.int/hq/2001/WHO\\_NHD\\_01.3.pdf](http://whqlibdoc.who.int/hq/2001/WHO_NHD_01.3.pdf), accessed 7 June 2011).
2. *Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity*. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011 (WHO/NMH/NHD/MNM/11.1; <http://www.who.int/vmnis/indicators/haemoglobin/en/index.html>, accessed March 2011).
3. WHO/CDC. *Worldwide prevalence of anaemia 1993–2005. WHO Global database on anaemia*. Geneva, World Health Organization, 2008 ([http://whqlibdoc.who.int/publications/2008/9789241596657\\_eng.pdf](http://whqlibdoc.who.int/publications/2008/9789241596657_eng.pdf), accessed 7 June 2011).
4. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. *Journal of Nutrition*, 2001, 131:S568–S579.
5. Lozoff B. Iron deficiency and child development. *Food and Nutrition Bulletin*, 2007, 28:S560–571.
6. De Maeyer EM et al. *Preventing and controlling iron deficiency anaemia through primary health care*. Geneva, World Health Organization, 1989 ([http://www.who.int/nutrition/publications/micronutrients/anaemia\\_iron\\_deficiency/9241542497/en/index.html](http://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/9241542497/en/index.html), accessed 16 June 2011).
7. Stoltzfus RJ. Iron interventions for women and children in low-income countries. *Journal of Nutrition*, 2011, 141:S756S–S762.
8. Gera T et al. Effect of iron supplementation on haemoglobin response in children: systematic review of randomised controlled trials. *Journal of Pediatric Gastroenterology and Nutrition*, 2007, 44:468–486.
9. Gillespie SR, Kevany J, Mason JB. *Controlling Iron Deficiency*. Administrative Committee on Coordination/Subcommittee on Nutrition State-of-the-Art Series. Geneva, UN Standing Committee on Nutrition, 1991 (Nutrition Policy Discussion Paper No. 9; [http://www.unscn.org/layout/modules/-resources/files/Policy\\_paper\\_No\\_9.pdf](http://www.unscn.org/layout/modules/-resources/files/Policy_paper_No_9.pdf), accessed 5 August 2011).
10. Viteri FE. Iron supplementation for the control of iron deficiency in populations at risk. *Nutrition Reviews*, 1997, 55:195–209.
11. Berger J et al. Weekly iron supplementation is as effective as 5 day per week iron supplementation in Bolivian school children living at high altitude. *European Journal of Clinical Nutrition*, 1997, 6:381–386.
12. Viteri FE et al. True absorption and retention of supplemental iron is more efficient when iron is administered every three days rather than daily to iron-normal and iron-deficient rats. *Journal of Nutrition*, 1995, 125:82–91.
13. Wright AJ, Southon S. The effectiveness of various iron supplementation regimens in improving the Fe status of anemic rats. *British Journal of Nutrition*, 1990, 63:579–585.
14. Baqui AH et al. Weekly iron supplementation does not block increases in serum zinc due to weekly zinc supplementation in Bangladeshi infants. *Journal of Nutrition*, 2005, 135:2187–2191.
15. National Institutes of Health. Iron and Malaria Technical Working Group. Chapter 2: Mechanisms. In: Raiten D, Namaste S, Brabin B, eds. *Considerations for the safe and effective use of iron interventions*. Bethesda, MD, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), 2011:16–51.
16. *Weekly iron and folic acid supplementation programmes for women of reproductive age: an analysis of best programme practices*. Manila, World Health Organization Regional Office for the Western Pacific, 2011.

17. De-Regil LM et al. Intermittent iron supplementation for improving nutrition and developmental outcomes in children under 12 years of age. *Cochrane Database of Systematic Reviews*, 2011 (12): CD009085 (<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009085.pub2/abstract>, accessed 15 December 2011).
18. *Global malaria report 2010*. Global Malaria Programme. Geneva, World Health Organization, 2010 ([http://whqlibdoc.who.int/publications/2010/9789241564106\\_eng.pdf](http://whqlibdoc.who.int/publications/2010/9789241564106_eng.pdf), accessed 7 June 2011).
19. Partnership for Child Development et al. *Malaria control in schools. A toolkit on effective education sector responses to malaria in Africa*, London, Partnership for Child Development, 2009 (<http://www.schoolsandhealth.org/Documents/Malaria%20Toolkit%20for%20Schools%202009.pdf>, accessed 29 June 2011).
20. Stoltzfus R, Dreyfuss M. *Guidelines for the use of iron supplements to prevent and treat iron deficiency anaemia*. Washington, DC, ILSI Press, 1998. ([http://www.who.int/nutrition/publications/micronutrients/-guidelines\\_for\\_iron\\_supplementation.pdf](http://www.who.int/nutrition/publications/micronutrients/-guidelines_for_iron_supplementation.pdf), accessed 5 August 2011).
21. WHO/FAO. *Vitamin and mineral requirements in human nutrition*, 2nd ed. Geneva, World Health Organization, 2004 (<http://www.who.int/nutrition/publications/micronutrients/9241546123/en/>, accessed 16 June 2011).
22. Hall A et al. A review and meta-analysis of the impact of intestinal worms on child growth and nutrition. *Maternal and Child Nutrition*, 2008, 4(Suppl. 1):118–236.
23. WHO/UNICEF joint statement. *Clinical management of acute diarrhoea*. Geneva, World Health Organization, 2004 ([http://www.who.int/child\\_adolescent\\_health/documents/who\\_fch\\_cah\\_04\\_7/en/index.html](http://www.who.int/child_adolescent_health/documents/who_fch_cah_04_7/en/index.html), accessed 16 June 2011).
24. *Quality assurance of pharmaceuticals: meeting a major public health challenge*. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Geneva, World Health Organization, 2007 ([http://www.who.int/medicines/publications/brochure\\_pharma.pdf](http://www.who.int/medicines/publications/brochure_pharma.pdf), accessed 16 June 2011).
25. *The international pharmacopoeia*, 4th ed. Geneva, World Health Organization, 2008 (<http://apps.who.int/phint/en/p/about>, accessed 16 June 2011).
26. WHO/CDC. *Logic model for micronutrient interventions in public health*. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011 (WHO/NMH/NHD/MNM/11.5; [http://www.who.int/vmnis/toolkit/WHO-CDC\\_Logic\\_Model\\_en.pdf](http://www.who.int/vmnis/toolkit/WHO-CDC_Logic_Model_en.pdf), accessed 16 June 2011).
27. *WHO handbook for guideline development*. Guidelines Review Committee. Draft March 2010. Geneva, World Health Organization, 2010.
28. Guyatt G et al. GRADE guidelines 1. Introduction – GRADE evidence profiles and summary of findings tables. *Journal of Clinical Epidemiology*, 2011, 64:383–394.
29. *Basic documents*, 47th ed. Geneva, World Health Organization, 2009 (<http://apps.who.int/gb/bd/>, accessed 19 May 2011).
30. *Guidelines for declaration of interests (WHO experts)*. Geneva, World Health Organization, 2010.

## Annex 1 GRADE “Summary of findings” tables

### Intermittent use of iron supplements versus placebo or no intervention in children 2 months –12 years of age

**Patient or population:** Children under 12 years of age

**Settings:** Community settings

**Intervention:** Intermittent supplementation with iron alone or with other micronutrients

**Comparison:** Placebo or no intervention

Outcomes	Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)*	Comments
<b>Anaemia (haemoglobin below a cut-off defined by the trialists, taking into account the age and altitude)</b>	<b>RR 0.51</b> (0.37–0.72)	1824 (10 studies)	⊕⊕⊕⊖ <b>moderate</b> <sup>1</sup>	
<b>Haemoglobin (g/l)</b>	<b>MD 5.20</b> (2.51–7.88)	3032 (19 studies)	⊕⊕⊖⊖ <b>low</b> <sup>2,3</sup>	
<b>Iron deficiency</b>	<b>RR 0.24</b> (0.06–0.91)	431 (3 studies)	⊕⊖⊖⊖ <b>very low</b> <sup>2,3,4</sup>	
<b>Iron deficiency anaemia</b>	Not estimable	0 (0 studies)	See comment	None of the trials reported on this outcome
<b>Ferritin (µg/l)</b>	<b>MD 14.17</b> (3.53–24.81)	550 (5 studies)	⊕⊕⊖⊖ <b>low</b> <sup>2,3</sup>	
<b>All-cause mortality</b>	Not estimable	0 (0 studies)	See comment	None of the trials reported on this outcome

CI, confidence interval; RR, risk ratio; MD, mean difference.

\*GRADE Working Group grades of evidence:

**High quality:** We are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate quality:** We have moderate confidence in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low quality:** Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.

**Very low quality:** We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of the effect.

<sup>1</sup> There was high statistical heterogeneity. Given the large and consistent effect (RR 0.51; 95% CI 0.37–0.72), the authors have refrained from downgrading even though three of 10 studies were at high risk of bias.

<sup>2</sup> High statistical heterogeneity but results were consistent.

<sup>3</sup> Some studies lacked blinding and clear methods of allocation.

<sup>4</sup> Wide confidence intervals.

Note: For cluster-randomized trials, the analyses only include the estimated effective sample size, after adjusting the data to account for the clustering effect.

For details of studies included in the review, see reference (17).

**Intermittent versus daily use of iron supplements in children under 12 years of age****Patient or population:** Children under 12 years of age**Settings:** Community settings**Intervention:** Intermittent supplementation with iron alone or with other micronutrients**Comparison:** Daily supplementation with iron alone or with other micronutrients

Outcomes	Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)*	Comments
<b>Anaemia (haemoglobin below a cut-off defined by the trialists, taking into account the age and altitude)</b>	<b>RR 1.23</b> (1.04–1.47)	980 (6 studies)	⊕⊕⊖⊖ <b>low</b> <sup>1,2</sup>	
<b>Haemoglobin (g/l)</b>	<b>MD –0.60</b> (–1.54, 0.35)	2834 (19 studies)	⊕⊕⊖⊖ <b>low</b> <sup>1,3</sup>	
<b>Iron deficiency</b>	<b>RR 4.00</b> (1.23–13.05)	76 (1 study)	⊕⊖⊖⊖ <b>very low</b> <sup>4</sup>	Only one study reported on this outcome
<b>Iron deficiency anaemia</b>	Not estimable	0 (0 studies)	See comment	None of the trials reported on this outcome
<b>Ferritin (µg/l)</b>	<b>MD –4.19</b> (–9.42 to 1.05)	902 (10 studies)	⊕⊕⊖⊖ <b>low</b> <sup>1,3</sup>	
<b>All-cause mortality</b>	Not estimable	0 (0 studies)	See comment	None of the trials reported on this outcome

CI, confidence interval; RR, risk ratio; MD, mean difference.

\*GRADE Working Group grades of evidence:

**High quality:** We are very confident that the true effect lies close to that of the estimate of the effect.**Moderate quality:** We have moderate confidence in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.**Low quality:** Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.**Very low quality:** We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of the effect.<sup>1</sup> Some studies lacked blinding and clear methods of randomization and allocation.<sup>2</sup> Wide confidence intervals.<sup>3</sup> High heterogeneity but results were mostly consistent.<sup>4</sup> Only one trial with unclear methods to generate the random sequence and conceal the allocation. Wide confidence intervals.

Note: For cluster-randomized trials, the analyses only include the estimated effective sample size, after adjusting the data to account for the clustering effect.

For details of studies included in the review, see reference (17).

## Annex 2 WHO Steering Committee for Nutrition Guidelines Development

### **Dr Ala Alwan**

Acting Director  
Department of Chronic Diseases and Health  
Promotion  
Noncommunicable Diseases and Mental Health  
(NMH) Cluster

### **Dr Francesco Branca**

Director  
Department of Nutrition for Health and  
Development  
Noncommunicable Diseases and Mental Health  
(NMH) Cluster

### **Dr Ruediger Krech**

Director  
Department of Ethics, Equity, Trade and  
Human Rights  
Information, Evidence and Research (IER)  
Cluster

### **Dr Knut Lonnroth**

Medical Officer  
The Stop TB Strategy  
HIV/AIDS, TB and Neglected Tropical Diseases  
(HTM) Cluster

### **Dr Daniel Eduardo Lopez Acuna**

Director  
Department of Strategy, Policy and Resource  
Management  
Health Action in Crises (HAC) Cluster

### **Dr Elizabeth Mason**

Director  
Department of Child and Adolescent Health  
and Development  
Family and Community Health (FCH) Cluster

### **Dr Michael Mbitvo**

Director  
Department of Reproductive Health and  
Research  
Family and Community Health (FCH) Cluster

### **Dr Jean-Marie Okwo-Bele**

Director  
Department of Immunization, Vaccines and  
Biologicals  
Family and Community Health (FCH) Cluster

### **Dr Gottfried Otto Hirschall**

Director  
Department of HIV/AIDS  
HIV/AIDS, TB and Neglected Tropical Diseases  
(HTM) Cluster

### **Dr Tikki Pangestu**

Director  
Department of Research Policy and  
Cooperation  
Information, Evidence and Research (IER)  
Cluster

### **Dr Isabelle Romieu**

Director  
Dietary Exposure Assessment Group, Nutrition  
and Metabolism Section  
International Agency for Research  
on Cancer (IARC)  
Lyons, France

### **Dr Sergio Spinaci**

Associate Director  
Global Malaria Programme  
HIV/AIDS, TB and Neglected Tropical Diseases  
(HTM) Cluster

### **Dr Willem Van Lerberghe**

Director  
Department of Health Policy, Development and  
Services  
Health Systems and Services (HSS) Cluster

### **Dr Maged Younes**

Director  
Department of Food Safety, Zoonoses and  
Foodborne Diseases  
Health Security and Environment (HSE) Cluster

### **Dr Nevio Zagaria**

Acting Director  
Department of Emergency Response and  
Recovery Operations  
Health Action in Crises (HAC) Cluster

## Annex 3

### Nutrition Guidance Expert Advisory Group (NUGAG) – Micronutrients, WHO Secretariat and external resource experts

#### A. NUGAG – Micronutrients

(Note: the areas of expertise of each guideline group member are given in italics)

**Ms Deena Alasfoor**

Ministry of Health  
Muscat, Oman  
*Health programme management, food legislations, surveillance in primary health care*

**Dr Beverley-Ann Biggs**

International and Immigrant Health Group  
Department of Medicine  
University of Melbourne  
Parkville, Australia  
*Micronutrients supplementation, clinical infectious diseases*

**Dr Héctor Bourges Rodríguez**

Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran  
Mexico City, Mexico  
*Nutritional biochemistry and metabolism research, food programmes, policy, and regulations*

**Dr Norm Campbell**

Departments of Medicine  
Community Health Sciences and Physiology and Pharmacology  
University of Calgary  
Calgary, Canada  
*Physiology and pharmacology, hypertension prevention and control*

**Dr Rafael Flores-Ayala**

Centers for Disease Control and Prevention (CDC)  
Atlanta, United States of America  
*Nutrition and human capital formation, nutrition and growth, impact of micronutrient interventions*

**Professor Malik Goonewardene**

Department of Obstetrics and Gynaecology  
University of Ruhuna  
Galle, Sri Lanka  
*Obstetrics and gynaecology, clinical practice*

**Dr Junsheng Huo**

National Institute for Nutrition and Food Safety  
Chinese Center for Disease Control and Prevention  
Beijing, China  
*Food fortification, food science and technology, standards and legislation*

**Dr Janet C. King**

Children's Hospital Oakland Research Institute  
Oakland, United States of America  
*Micronutrients, maternal and child nutrition, dietary requirements*

**Dr Marzia Lazzerini**

Department of Paediatrics and Unit of Research on Health Services and International Health  
Institute for Maternal and Child Health IRCCS Burlo Garofolo  
Trieste, Italy  
*Paediatrics, malnutrition, infectious diseases*

**Professor Malcolm E. Molyneux**

College of Medicine – University of Malawi  
Blantyre, Malawi  
*Malaria, international tropical diseases research and practice*

**Engineer Wisam Qarqash**

Jordan Health Communication Partnership  
Johns Hopkins University  
Bloomberg School of Public Health  
Amman, Jordan  
*Design, implementation and evaluation of health communications and programmes*

**Dr Daniel Raiten**

Office of Prevention Research and International Programs  
National Institutes of Health (NIH)  
Bethesda, United States of America  
*Malaria, maternal and child health, human development research*

---

**Dr Mahdi Ramsan Mohamed**

Research Triangle Institute (RTI) International  
Dar es Salaam, the United Republic of Tanzania  
*Malaria control and prevention, neglected tropical diseases*

**Dr Meera Shekar**

Health Nutrition Population  
Human Development Network (HDNHE)  
The World Bank  
Washington, DC, United States of America  
*Costing of interventions in public health nutrition, programme implementation*

**Dr Rebecca Joyce Stoltzfus**

Division of Nutritional Sciences  
Cornell University  
Ithaca, United States of America  
*International nutrition and public health, iron and vitamin A nutrition, programme research*

**Ms Carol Tom**

Central and Southern African Health  
Community (ECSA)  
Arusha, the United Republic of Tanzania  
*Food fortification technical regulations and standards, policy harmonization*

**Dr David Tovey**

The Cochrane Library  
Cochrane Editorial Unit  
London, England  
*Systematic reviews, health communications, evidence for primary health care*

**Mrs Vilma Qahoush Tyler**

UNICEF Regional Office for Central and Eastern  
Europe and  
Commonwealth of Independent States (CEE/CIS)  
Geneva, Switzerland  
*Food fortification, public health programmes*

**Dr Gunn Elisabeth Vist**

Department of Preventive and International  
Health  
Norwegian Knowledge Centre for the Health  
Services  
Oslo, Norway  
*Systematic review methods and evidence assessment using GRADE methodology*

**Dr Emorn Wasantwisut**

Mahidol University  
Nakhon Pathom, Thailand  
*International nutrition, micronutrient biochemistry and metabolism*

---

**B. WHO****Mr Joseph Ashong**

Intern (rapporteur)  
Micronutrients Unit  
Department of Nutrition for Health and  
Development

**Dr Maria del Carmen Casanovas**

Technical Officer  
Nutrition in the Life Course Unit  
Department of Nutrition for Health and  
Development

**Dr Bernadette Daelmans**

Medical Officer  
Newborn and Child Health and Development  
Unit  
Department of Child and Adolescent Health  
and Development

**Dr Luz Maria de Regil**

Epidemiologist  
Micronutrients Unit  
Department of Nutrition for Health and  
Development

**Dr Chris Duncombe**

Medical Officer  
Anti-retroviral Treatment and HIV Care Unit  
Department of HIV/AIDS

**Dr Olivier Fontaine**

Medical Officer  
Newborn and Child Health and Development  
Unit  
Department of Child and Adolescent Health  
and Development

---

**Dr Davina Gherzi**  
Team Leader  
International Clinical Trials Registry Platform  
Department of Research Policy and  
Cooperation

**Dr Ahmet Metin Gulmezoglu**  
Medical Officer  
Technical Cooperation with Countries for  
Sexual and Reproductive Health  
Department of Reproductive Health and  
Research

**Dr Regina Kulier**  
Scientist  
Guideline Review Committee Secretariat  
Department of Research Policy and  
Cooperation

**Dr José Martinez**  
Coordinator  
Newborn and Child Health and Development  
Unit  
Department of Child and Adolescent Health  
and Development

**Dr Matthews Mathai**  
Medical Officer  
Department of Making Pregnancy Safer

**Dr Mario Meriardi**  
Coordinator  
Improving Maternal and Perinatal Health Unit  
Department of Reproductive Health and  
Research

**Dr Sant-Rayn Pasricha**  
Intern (rapporteur)  
Micronutrients Unit  
Department of Nutrition for Health and  
Development

**Dr Juan Pablo Peña-Rosas**  
Coordinator  
Micronutrients Unit  
Department of Nutrition for Health and  
Development

**Dr Aafje Rietveld**  
Medical Officer  
Global Malaria Programme

**Dr Lisa Rogers**  
Technical Officer  
Micronutrients Unit  
Department of Nutrition for Health and  
Development

**Mr Anand Sivasankara Kurup**  
Technical Officer  
Social Determinants of Health Unit  
Department of Ethics, Equity, Trade and  
Human Rights Information

**Dr Joao Paulo Souza**  
Medical Officer  
Technical Cooperation with Countries for  
Sexual and Reproductive Health  
Department of Reproductive Health and  
Research

**Dr Severin Von Xylander**  
Medical Officer  
Department of Making Pregnancy Safer

**Dr Godfrey Xuereb**  
Technical Officer  
Surveillance and Population-based  
Prevention Unit  
Department of Chronic Diseases and Health  
Promotion

---

### C. WHO regional offices

**Dr Abel Dushimimana**  
Medical Officer  
Nutrition  
WHO Regional Office for Africa  
Brazzaville, Congo

**Dr Chessa Lutter**  
Regional Adviser  
Child and Adolescent Health  
WHO Regional Office for the Americas/Pan  
American Health Organization  
Washington, DC, United States of America

---

**Dr Kunal Bagchi**

Regional Adviser  
Nutrition and Food Safety  
WHO Regional Office for South-East Asia  
New Delhi, India

**Dr Joao Breda**

Noncommunicable Diseases and Environment  
WHO Regional Office for Europe  
Copenhagen, Denmark

**Dr Ayoub Al-Jawaldeh**

Regional Adviser  
Nutrition  
WHO Regional Office for the Eastern  
Mediterranean  
Cairo, Egypt

**Dr Tommaso Cavalli-Sforza**

Regional Adviser  
Nutrition  
WHO Regional Office for the Western Pacific  
Manila, Philippines

---

**D. External resource experts****Dr Andreas Bluethner**

BASF SE  
Limburgerhof, Germany

**Dr Denise Coitinho Delmuè**

United Nations System Standing Committee on  
Nutrition (SCN)  
Geneva, Switzerland

**Professor Richard Hurrell**

Laboratory of Human Nutrition  
Swiss Federal Institute of Technology  
Zurich, Switzerland

**Dr Guansheng Ma**

National Institute for Nutrition and Food Safety  
Chinese Center for Disease Control and  
Prevention  
Beijing, China

**Dr Regina Moench-Pfanner**

Global Alliance for Improved Nutrition (GAIN)  
Geneva, Switzerland

**Ms Sorrel Namaste**

Office of Prevention Research and International  
Programs  
National Institutes of Health (NIH)  
Bethesda, United States of America

**Dr Lynnette Neufeld**

Micronutrient Initiative  
Ottawa, Canada

**Dr Juliana Ojukwu**

Department of Paediatrics  
Ebonyi State University  
Abakaliki, Nigeria

**Dr Mical Paul**

Infectious Diseases Unit  
Rabin Medical Center  
Belinson Hospital and Sackler Faculty of  
Medicine  
Tel Aviv University  
Petah-Tikva, Israel

**Mr Arnold Timmer**

United Nations Children's Fund (UNICEF)  
New York, United States of America

**Dr Stanley Zlotkin**

Division of Gastroenterology, Hepatology and  
Nutrition  
The Hospital for Sick Children  
Toronto, Canada

## Annex 4 External Experts and Stakeholders Panel – Micronutrients

**Dr Ahmadwali Aminee**

Micronutrient Initiative  
Kabul, Afghanistan

**Dr Mohamd Ayoya**

United Nations Children's Fund (UNICEF)  
Port Au-Prince, Haiti

**Dr Salmeh Bahmanpour**

Shiraz University of Medical Sciences  
Shiraz, Iran (Islamic Republic of)

**Mr Eduard Baladia**

Spanish Association of Dieticians and Nutritionists  
Barcelona, Spain

**Dr Levan Baramidze**

Ministry of Labour  
Health and Social Affairs  
Tbilisi, Georgia

**Mr Julio Pedro Basulto Marset**

Spanish Association of Dieticians and Nutritionists  
Barcelona, Spain

**Dr Christine Stabell Benn**

Bandim Health Project  
Statens Serum Institut  
Copenhagen, Denmark

**Dr Jacques Berger**

Institut de Recherche pour le Développement  
Montpellier, France

**Dr R.J. Berry**

Centers for Disease Control and Prevention (CDC)  
Atlanta, United States of America

**Ms E.N. (Nienke) Blok**

Ministry of Health, Welfare and Sport  
The Hague, the Netherlands

**Ms Lucie Bohac**

Iodine Network  
Ottawa, Canada

**Dr Erick Boy-Gallego**

HarvestPlus  
Ottawa, Canada

**Dr Mario Bracco**

Albert Einstein Social Responsibility Israeli Institute  
São Paulo, Brazil

**Dr Gerard N. Burrow**

International Council of Iodine Deficiency Disorders  
Ottawa, Canada

**Dr Christine Clewes**

Global Alliance for Improved Nutrition  
Geneva, Switzerland

**Dr Bruce Cogill**

Global Alliance for Improved Nutrition  
Geneva, Switzerland

**Mr Hector Cori**

DSM  
Santiago, Chile

**Dr Maria Claret Costa Monteiro Hadler**

Federal University of Goiás  
Goiânia, Brazil

**Ms Nita Dalmiya**

United Nations Children's Fund (UNICEF)  
New York, United States of America

**Professor Ian Darnton-Hill**

University of Sydney  
Sydney, Australia

**Professor Kathryn Dewey**

University of California  
Davis, United States of America

**Professor Michael Dibley**

Sydney School of Public Health  
University of Sydney  
Sydney, Australia

**Dr Marjoleine Dijkhuizen**

University of Copenhagen  
Copenhagen, Denmark

**Ms Tatyana El-Kour**

World Health Organization  
Amman, Jordan

**Dr Suzanne Filteau**

London School of Hygiene and Tropical Medicine  
London, England

**Dr Rodolfo F. Florentino**

Nutrition Foundation of the Philippines  
Manila, Philippines

**Dr Ann Fowler**  
DSM Nutritional Products  
Rheinfelden, Switzerland

**Mr Joby George**  
Save the Children  
Lilongwe, Malawi

**Dr Abdollah Ghavami**  
School of Human Sciences  
London Metropolitan University  
London, England

**Dr Rosalind Gibson**  
Department of Human Nutrition  
University of Otago  
Dunedin, New Zealand

**Mr Nils Grede**  
World Food Programme  
Rome, Italy

**Ms Fofoa R. Gulugulu**  
Public Health Unit  
Ministry of Health  
Funafuti, Tuvalu

**Dr Andrew Hall**  
University of Westminster  
London, England

**Mr Richard L. Hanneman**  
Salt Institute  
Alexandria, United States of America

**Ms Kimberly Harding**  
Micronutrient Initiative  
Ottawa, Canada

**Dr Suzanne S. Harris**  
International Life Sciences Institute (ILSI)  
Washington, DC, United States of America

**Dr Phil Harvey**  
Philip Harvey Consulting  
Rockville, United States of America

**Dr Izzeldin S. Hussein**  
International Council for Control of Iodine  
Deficiency Disorders  
Al Khuwair, Oman

**Dr Susan Jack**  
University of Otago  
Dunedin, New Zealand

**Mr Quentin Johnson**  
Food Fortification  
Quican Inc.  
Rockwood, Canada

**Mr Vinod Kapoor**  
Independent Consultant on Fortification  
Panchkula, India

**Dr Klaus Kraemer**  
Sight and Life  
Basel, Switzerland

**Dr Roland Kupka**  
UNICEF Regional Office for West and Central  
Africa  
Dakar, Senegal

**Ms Ada Lauren**  
Vitamin Angels Alliance  
Santa Barbara, United States of America

**Dr Daniel Lopez de Romaña**  
Instituto de Nutrición y Tecnología de Alimentos  
(INTA)  
Universidad de Chile  
Santiago, Chile

**Mrs Maria Manera**  
Spanish Association of Dieticians and  
Nutritionists  
Girona, Spain

**Dr Homero Martinez**  
RAND Corporation  
Santa Monica, United States of America

**Dr Zouhir Massen**  
Faculty of Medicine  
University of Tlemcen  
Tlemcen, Algeria

**Dr Abdelmonim Medani**  
Sudan Atomic Energy  
Khartoum, Sudan

**Dr María Teresa Murguía Peniche**  
National Center for Child and Adolescent Health  
Mexico City, Mexico

**Dr Sirimavo Nair**  
University of Baroda  
Vadodara, India

**Dr Ruth Oniango**

*African Journal of Food, Agriculture, Nutrition and Development (AJFAND)*  
Nairobi, Kenya

**Dr Saskia Osendarp**

Science Leader Child Nutrition  
Unilever R&D  
Vlaardingen, the Netherlands

**Dr Jee Hyun Rah**

DSM-WFP Partnership  
DSM – Sight and Life  
Basel, Switzerland

**Mr Sherali Rahmatulloev**

Ministry of Health  
Dushanbe, Tajikistan

**Ms Anna Roesler**

Menzies School of Health Research/  
Compass Women's and Children's Knowledge  
Hub for Health  
Chiang Mai, Thailand

**Professor Irwin Rosenberg**

Tufts University  
Boston, United States of America

**Professor Amal Mamoud Saeid Taha**

Faculty of Medicine  
University of Khartoum  
Khartoum, Sudan

**Dr Isabella Sagoe-Moses**

Ghana Health Service  
Accra, Ghana

**Dr Dia Sanou**

Department of Applied Human Nutrition  
Mount Saint Vincent University  
Halifax, Canada

**Dr Rameshwar Sarma**

St James School of Medicine  
Bonaire, the Netherlands Antilles

**Dr Andrew Seal**

University College London  
Centre for International Health and Development  
London, England

**Dr Magdy Shehata**

World Food Programme  
Cairo, Egypt

**Mr Georg Steiger**

DSM Nutritional Products  
DSM Life Science Products International  
Basel, Switzerland

**Professor Barbara Stoecker**

Oklahoma State University  
Oklahoma City, United States of America

**Dr Ismael Teta**

Micronutrient Initiative  
Ottawa, Canada

**Dr Ulla Uusitalo**

University of South Florida  
Tampa, United States of America

**Dr Hans Verhagen**

Centre for Nutrition and Health  
National Institute for Public Health and the  
Environment (RIVM)  
Bilthoven, the Netherlands

**Dr Hans Verhoef**

Wageningen University  
Wageningen, the Netherlands

**Dr Sheila Vir Chander**

Public Health Nutrition Development Centre  
New Delhi, India

**Dr Annie Wesley**

Micronutrient Initiative  
Ottawa, Canada

**Dr Frank Wieringa**

Institut de Recherche pour le Développement  
Montpellier, France

**Ms Caroline Wilkinson**

United Nations High Commission for Refugees  
Geneva, Switzerland

**Dr Pascale Yunis**

American University of Beirut Medical Center  
Beirut, Lebanon

**Dr Lingxia Zeng**

Xi'an JiaoTong University College of Medicine  
Xi'an, China

## Annex 5 Questions in Population, Intervention, Control, Outcomes (PICO) format

### 1. Effects and safety of iron supplementation in children 24–59 months of age


- a. Should iron supplements be given to children 24–59 months of age to improve health outcomes?
- b. If so, at what dose, frequency and duration of the intervention, and in which settings?

<b>Population:</b>	Children 24–59 months of age <ul style="list-style-type: none"><li>• Subpopulation: <i>Critical</i><ul style="list-style-type: none"><li>• By previous exposure to iron: infants who regularly received an iron supplement within the first 23 months of life versus no iron</li><li>• By malaria (no transmission or elimination achieved, susceptibility to epidemic malaria, year-round transmission with marked seasonal fluctuations, year-round transmission with consideration of <i>Plasmodium falciparum</i> and/or <i>Plasmodium vivax</i>)</li><li>• By use of concurrent antimalarial measures introduced in the study: yes versus no</li><li>• By antimalarial measures implemented by the health system: yes versus no</li><li>• By anaemia status of population: more than 40% versus 40% or less</li></ul></li></ul>
<b>Intervention:</b>	Iron supplementation <ul style="list-style-type: none"><li>• Subgroup analysis: <i>Critical</i><ul style="list-style-type: none"><li>• By dose: 2 mg/kg/day versus other</li><li>• By frequency: daily versus weekly versus flexible</li><li>• By duration: 3 months or less versus more than 3 months</li><li>• By nutrient: in combination with other micronutrients or not</li><li>• By targeting: universal versus prescribed</li></ul></li></ul>
<b>Control:</b>	<ul style="list-style-type: none"><li>• No iron supplementation</li><li>• Placebo</li><li>• Same supplement without iron</li></ul>
<b>Outcomes:</b>	<i>Critical</i> <ul style="list-style-type: none"><li>• Anaemia</li><li>• Iron deficiency anaemia</li><li>• Iron deficiency</li><li>• Morbidity<ul style="list-style-type: none"><li>– Malaria incidence and severity (parasitaemia with or without symptoms)</li></ul></li><li>• Growth measures: underweight, stunting status, head circumference</li><li>• Mortality<ul style="list-style-type: none"><li>– All-cause</li><li>– Malaria</li></ul></li></ul>
<b>Setting:</b>	All countries

## 2. Effects and safety of iron supplementation in children 60 months of age and older

- a. Should iron supplements be given to children 60 months of age and older to improve health outcomes?
- b. If so, at what dose, frequency and duration of the intervention, and in which settings?

<b>Population:</b>	Children 60 months of age and older <ul style="list-style-type: none"><li>• Subpopulation: <i>Critical</i><ul style="list-style-type: none"><li>• By previous exposure to iron: children who regularly received an iron supplement within the first 59 months of life versus no iron</li><li>• By malaria (no transmission or elimination achieved, susceptibility to epidemic malaria, year-round transmission with marked seasonal fluctuations, year-round transmission with consideration of <i>Plasmodium falciparum</i> and/or <i>Plasmodium vivax</i>)</li><li>• By use of concurrent antimalarial measures introduced in the study: yes versus no</li><li>• By antimalarial measures implemented by the health system: yes versus no</li><li>• By anaemia status of population: more than 40% versus 40% or less</li><li>• By individual's status of anaemia: anaemic versus non-anaemic</li></ul></li></ul>
<b>Intervention:</b>	Iron supplementation <ul style="list-style-type: none"><li>• Subgroup analysis: <i>Critical</i><ul style="list-style-type: none"><li>• By dose: 2 mg/kg/day versus other</li><li>• By frequency: daily versus weekly versus flexible</li><li>• By duration: 3 months or less versus more than 3 months</li><li>• By nutrient: in combination with other micronutrients or not</li><li>• By targeting: universal versus prescribed</li></ul></li></ul>
<b>Control:</b>	<ul style="list-style-type: none"><li>• No iron supplementation</li><li>• Placebo</li><li>• Same supplement without iron</li></ul>
<b>Outcomes:</b>	<i>Critical</i> <ul style="list-style-type: none"><li>• Anaemia</li><li>• Iron deficiency anaemia</li><li>• Iron deficiency</li><li>• Morbidity<ul style="list-style-type: none"><li>– Malaria incidence and severity (parasitaemia with or without symptoms)</li></ul></li><li>• Growth measures: underweight, stunting status, head circumference</li><li>• Mortality<ul style="list-style-type: none"><li>– All-cause</li><li>– Acute respiratory infections</li><li>– Diarrhoea</li><li>– Malaria</li></ul></li></ul>
<b>Setting:</b>	All countries



## Annex 6 Summary of NUGAG members' considerations for determining the strength of the recommendation

- Quality of evidence:**
- The quality of the evidence was considered sufficient to support a recommendation in all settings, including areas of malaria transmission
  - High value was placed on the successful implementation of pilot programmes in both children and menstruating women in some countries
- Values and preferences:**
- Intermittent use of iron supplements can increase adherence as it might be easier for children and their caregivers to follow the intervention with less inconvenience
  - The regular and less frequent provision of iron supplements could be a good preventive measure in public health programmes where daily iron supplementation regimens are non-existent or are not being successfully implemented at scale
- Trade-off between benefits and harm:**
- Improved iron status may have long-term benefits and is likely to have a benefit on quality of life and development
  - Clear benefits outweigh any potential minimal harms
- Cost and feasibility:**
- This intervention is perceived as less costly compared with daily iron supplementation
  - Implementation of intermittent supplementation may be particularly feasible in facilities such as schools, because supplements can be given throughout the school calendar year, reaching the target population with good acceptability. However, it is important that this intervention also reaches those children who are outside the school system
  - This intervention should be considered in the context of all other options to improve iron nutrition

**For more information, please contact:**

Department of Nutrition for Health and Development

World Health Organization

Avenue Appia 20, CH-1211 Geneva 27, Switzerland

Fax: +41 22 791 4156

E-mail: [nutrition@who.int](mailto:nutrition@who.int)

[www.who.int/nutrition](http://www.who.int/nutrition)



ISBN 978 92 4 150200 9



9 789241 502009